APPLY NOW - TRANSVAC CALL OPEN

The fourth round of applications for access to the TRANSVAC infrastructure services is now closed. You can now apply for the next round with the Deadline 31 January 2012.

The call will remain open for the duration of the project (until Sept 2013) or until all of the services have been exhausted. Applications will be processed in batches. The deadline for the next batch is 31 January 2012.

Go to www.transvac.org for more info.

Mission

The current lack of harmonisation of malaria vaccine assay conduct coupled with the lack of an enabling environment for comparing research results leads to scepticism about the comparability of assay results. Assay harmonisation is a central priority to enable rational malaria vaccine design and for decision-making in vaccine development.

The overall goal of this three year project is to develop harmonised assays to facilitate comparison of results and improve decision making on vaccine construct development, product characterisation, down selection of candidates and/or formulation, and clinical development plans.

The project involves thirteen partner institutions and is  funded by the European Commission's Framework Program 7 (FP7) as Coordination and Support Action, project number: 223126, with €1 000 000 and by additional complementary contributions from the PATH Malaria Vaccine Initiative and the Centers for Disease Control and Prevention. 

The official starting date of the project is 1st April  2009.


NEWS

Welcome to a new member of EVI Staff

Nicola Katrin Viebig takes up her duties as Project Manager on 2 May. EVI extends a warm welcome to Nicola, who will be working on projects funded by EDCTP, EC, and EVI.

TRANSVAC Project: 1st Workshop on Animal Models, May 12, 2011, NL

TRANSVAC offers a free workshop on harmonisation and standardisation of animal models in vaccine development. 

Towards validated assays for key immunological outcomes

To highlight the importance of assay harmonisation in malaria vaccine development, the OPTIMALVAC Consortium has published the position paper “Towards validated assays for key immunological outcomes”. Vaccine 29 (2011) 3093–3095

Syndicate content